Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Zorblisa in Epidermolysis Bullosa (SD-006)
NCT02670330Phase 3Terminated
- Sponsor
- Scioderm
- Start
- Jun 2015
- Primary completion
- Sep 2018
- Modality
- Transdermal Patches, Hydrogel Systems, Small Molecules
- Countries
- 12
01
Overview
Phase 3, open-label, single-arm trial of allantoin in epidermolysis bullosa (EB), sponsored by Scioderm. Primary endpoint: Treatment Emergent Adverse Events at 37 months. Started Jun 2015; status: terminated.
02
Drugs
allantoin
03
Conditions
epidermolysis bullosa (EB)
Beyond the preview
Go deeper on NCT02670330.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02670330.